Details
Stereochemistry | ACHIRAL |
Molecular Formula | C8H12N2O3 |
Molecular Weight | 184.1925 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCC1(CC)C(=O)NC(=O)NC1=O
InChI
InChIKey=FTOAOBMCPZCFFF-UHFFFAOYSA-N
InChI=1S/C8H12N2O3/c1-3-8(4-2)5(11)9-7(13)10-6(8)12/h3-4H2,1-2H3,(H2,9,10,11,12,13)
Barbital, the one of the series of barbiturates, has hypnotic, sedative, and anticonvulsant properties and used under the trade name Veronal. It calmed manic patients and helped melancholic patients to sleep and was an effective inducer of sleep in insomniacs, but at the same time compound could induced dependence. It was substituted by the butyl analog, butobarbital, which was three times stronger and its period of action was much shorter due to its lipophilicity. Barbital is a ligand of GABA-receptor complex and in addition, it could have another target, a creatine kinase.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: GABA receptor Sources: https://www.ncbi.nlm.nih.gov/pubmed/1654164 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Veronal Approved UseUnknown |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
300 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/957863/ |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
BARBITAL plasma | Rattus norvegicus population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
3860 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/957863/ |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
BARBITAL plasma | Rattus norvegicus population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
6 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/957863/ |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
BARBITAL plasma | Rattus norvegicus population: HEALTHY age: ADULT sex: MALE food status: FASTED |
Doses
Dose | Population | Adverse events |
---|---|---|
5 g 1 times / day single, oral Studied dose Dose: 5 g, 1 times / day Route: oral Route: single Dose: 5 g, 1 times / day Sources: |
unhealthy, 19 years n = 1 Health Status: unhealthy Condition: drug withdrawal Age Group: 19 years Sex: M Population Size: 1 Sources: |
Other AEs: Coma... |
250 mg 3 times / day multiple, oral Studied dose Dose: 250 mg, 3 times / day Route: oral Route: multiple Dose: 250 mg, 3 times / day Sources: |
unhealthy, median age 44 years n = 35 Health Status: unhealthy Condition: alcohol withdrawal symptoms Age Group: median age 44 years Sex: M+F Population Size: 35 Sources: |
Other AEs: Dizziness, Drug intoxication... Other AEs: Dizziness Sources: Drug intoxication Euphoric Tiredness |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Coma | 5 g 1 times / day single, oral Studied dose Dose: 5 g, 1 times / day Route: oral Route: single Dose: 5 g, 1 times / day Sources: |
unhealthy, 19 years n = 1 Health Status: unhealthy Condition: drug withdrawal Age Group: 19 years Sex: M Population Size: 1 Sources: |
|
Dizziness | 250 mg 3 times / day multiple, oral Studied dose Dose: 250 mg, 3 times / day Route: oral Route: multiple Dose: 250 mg, 3 times / day Sources: |
unhealthy, median age 44 years n = 35 Health Status: unhealthy Condition: alcohol withdrawal symptoms Age Group: median age 44 years Sex: M+F Population Size: 35 Sources: |
|
Drug intoxication | 250 mg 3 times / day multiple, oral Studied dose Dose: 250 mg, 3 times / day Route: oral Route: multiple Dose: 250 mg, 3 times / day Sources: |
unhealthy, median age 44 years n = 35 Health Status: unhealthy Condition: alcohol withdrawal symptoms Age Group: median age 44 years Sex: M+F Population Size: 35 Sources: |
|
Euphoric | 250 mg 3 times / day multiple, oral Studied dose Dose: 250 mg, 3 times / day Route: oral Route: multiple Dose: 250 mg, 3 times / day Sources: |
unhealthy, median age 44 years n = 35 Health Status: unhealthy Condition: alcohol withdrawal symptoms Age Group: median age 44 years Sex: M+F Population Size: 35 Sources: |
|
Tiredness | 250 mg 3 times / day multiple, oral Studied dose Dose: 250 mg, 3 times / day Route: oral Route: multiple Dose: 250 mg, 3 times / day Sources: |
unhealthy, median age 44 years n = 35 Health Status: unhealthy Condition: alcohol withdrawal symptoms Age Group: median age 44 years Sex: M+F Population Size: 35 Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
Modifying potential of thirty-one chemicals on the short-term development of gamma-glutamyl transpeptidase-positive foci in diethylnitrosamine-initiated rat liver. | 1984 Oct |
|
Comparative tumor-promoting activities of phenobarbital, amobarbital, barbital sodium, and barbituric acid on livers and other organs of male F344/NCr rats following initiation with N-nitrosodiethylamine. | 1985 Feb |
|
Drugs as allergens: the molecular basis of IgE binding to thiopentone. | 1987 |
|
The chronic hepatic or renal toxicity of di(2-ethylhexyl) phthalate, acetaminophen, sodium barbital, and phenobarbital in male B6C3F1 mice: autoradiographic, immunohistochemical, and biochemical evidence for levels of DNA synthesis not associated with carcinogenesis or tumor promotion. | 1988 Dec |
|
Induction of CYP2B1 mediated pentoxyresorufin O-dealkylase activity in different species, sex and tissue by prototype 2B1-inducers. | 1995 Mar 30 |
|
Stability of thiopental and pentobarbital in human plasma determined with a new easy and specific gas chromatography-mass spectrometry assay. | 1999 Aug |
|
Determination of barbiturates in urine by micellar liquid chromatography and direct injection of sample. | 1999 Nov |
|
Mouse skin passage of a Streptococcus pyogenes Tn917 mutant of sagA/pel restores virulence, beta-hemolysis and sagA/pel expression without altering the position or sequence of the transposon. | 2001 |
|
Molecular "chaperones" guide the spontaneous formation of a 15-component hydrogen-bonded assembly. | 2002 Jul 3 |
|
Supramolecular synthons based on N-H...N and C-H...O hydrogen bonds. Crystal engineering of a helical structure with 5,5-diethylbarbituric acid. | 2002 Sep 7 |
|
Biochemical mechanism of the effect of barbital on rifamycin B biosynthesis by Amycolatopsis mediterranei (M18 strain). | 2003 |
|
Complexation of phenolic guests by endo- and exo-hydrogen-bonded receptors. | 2003 Jul 21 |
|
Rational design of the first closed coordination capsule with octahedral outer shape. | 2004 May 3 |
|
The history of barbiturates a century after their clinical introduction. | 2005 Dec |
|
Rescue of heterochromatin organization in Hutchinson-Gilford progeria by drug treatment. | 2005 Nov |
|
Heme oxygenase, aminolevulinate acid synthetase and the antioxidant system in the brain of mice treated with porphyrinogenic drugs. | 2005 Oct 3 |
|
Statin-induced expression of CD59 on vascular endothelium in hypoxia: a potential mechanism for the anti-inflammatory actions of statins in rheumatoid arthritis. | 2006 |
|
Carbonic anhydrase in Tectona grandis: kinetics, stability, isozyme analysis and relationship with photosynthesis. | 2006 Aug |
|
Analysis of C4 and the C4 binding protein in the MRL/lpr mouse. | 2007 |
|
Proximal visceral endoderm and extraembryonic ectoderm regulate the formation of primordial germ cell precursors. | 2007 Dec 20 |
|
Modulation of the complement system by human beta-defensin 2. | 2007 Jan 10 |
|
Deletion of complement factor H-related genes CFHR1 and CFHR3 is associated with atypical hemolytic uremic syndrome. | 2007 Mar 16 |
|
Surviving mousepox infection requires the complement system. | 2008 Dec |
|
Application of two different kinds of sera against the Proteus penneri lipopolysaccharide core region in search of epitopes determining cross-reactions with antibodies. | 2008 Mar-Apr |
|
EspJ of enteropathogenic and enterohaemorrhagic Escherichia coli inhibits opsono-phagocytosis. | 2008 May |
|
Pharmacological profiles of animal- and nonanimal-derived sulfated polysaccharides--comparison of unfractionated heparin, the semisynthetic glucan sulfate PS3, and the sulfated polysaccharide fraction isolated from Delesseria sanguinea. | 2009 Apr |
|
Biomass production potential of a wastewater alga Chlorella vulgaris ARC 1 under elevated levels of CO₂and temperature. | 2009 Feb |
|
Interpain A, a cysteine proteinase from Prevotella intermedia, inhibits complement by degrading complement factor C3. | 2009 Feb |
|
Complement consumption in children with Plasmodium falciparum malaria. | 2009 Jan 9 |
|
The glyceraldehyde-3-phosphate dehydrogenase and the small GTPase Rab 2 are crucial for Brucella replication. | 2009 Jun |
|
Some patients with NHL possessed immunoreactivity to gliadin and to cow's milk proteins. | 2009 Sep |
|
Role of genetic polymorphisms in factor H and MBL genes in Tunisian patients with immunoglobulin A nephropathy. | 2010 |
|
Recombinant human complement component C2 produced in a human cell line restores the classical complement pathway activity in-vitro: an alternative treatment for C2 deficiency diseases. | 2010 Aug 20 |
|
Annexin-II, DNA, and histones serve as factor H ligands on the surface of apoptotic cells. | 2010 Feb 5 |
|
Determining the reactivity and titre of serum using a haemagglutination assay. | 2010 Jan 29 |
|
Combination of pneumococcal surface protein A (PspA) with whole cell pertussis vaccine increases protection against pneumococcal challenge in mice. | 2010 May 27 |
|
Complement factor H-related proteins CFHR2 and CFHR5 represent novel ligands for the infection-associated CRASP proteins of Borrelia burgdorferi. | 2010 Oct 20 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/21433434
10 g two times per day
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/16609694
It was reported the action of sodium barbital as an inhibitor of rabbit-muscle creatine kinase (CK), which plays a significant role in energy homeostasis in the muscles. The activity of CK underwent a rapid decrease when the concentration of sodium barbital was increased to 8 mmol/L, and the residual activity was about 35% of then active CK. The activity of CK dropped slowly until it was almost 0 when the concentration of sodium barbital was increased to 125 mmol/L. These results indicated that sodium barbital might function as an inhibitor of CK.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
DEA NO. |
2145
Created by
admin on Fri Dec 15 15:01:03 UTC 2023 , Edited by admin on Fri Dec 15 15:01:03 UTC 2023
|
||
|
WHO-VATC |
QN05CA04
Created by
admin on Fri Dec 15 15:01:03 UTC 2023 , Edited by admin on Fri Dec 15 15:01:03 UTC 2023
|
||
|
NCI_THESAURUS |
C67084
Created by
admin on Fri Dec 15 15:01:03 UTC 2023 , Edited by admin on Fri Dec 15 15:01:03 UTC 2023
|
||
|
WHO-ATC |
N05CA04
Created by
admin on Fri Dec 15 15:01:03 UTC 2023 , Edited by admin on Fri Dec 15 15:01:03 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
1325
Created by
admin on Fri Dec 15 15:01:03 UTC 2023 , Edited by admin on Fri Dec 15 15:01:03 UTC 2023
|
PRIMARY | RxNorm | ||
|
D001462
Created by
admin on Fri Dec 15 15:01:03 UTC 2023 , Edited by admin on Fri Dec 15 15:01:03 UTC 2023
|
PRIMARY | |||
|
5WZ53ENE2P
Created by
admin on Fri Dec 15 15:01:03 UTC 2023 , Edited by admin on Fri Dec 15 15:01:03 UTC 2023
|
PRIMARY | |||
|
m2227
Created by
admin on Fri Dec 15 15:01:03 UTC 2023 , Edited by admin on Fri Dec 15 15:01:03 UTC 2023
|
PRIMARY | Merck Index | ||
|
DB01483
Created by
admin on Fri Dec 15 15:01:03 UTC 2023 , Edited by admin on Fri Dec 15 15:01:03 UTC 2023
|
PRIMARY | |||
|
379
Created by
admin on Fri Dec 15 15:01:03 UTC 2023 , Edited by admin on Fri Dec 15 15:01:03 UTC 2023
|
PRIMARY | |||
|
31352
Created by
admin on Fri Dec 15 15:01:03 UTC 2023 , Edited by admin on Fri Dec 15 15:01:03 UTC 2023
|
PRIMARY | |||
|
57-44-3
Created by
admin on Fri Dec 15 15:01:03 UTC 2023 , Edited by admin on Fri Dec 15 15:01:03 UTC 2023
|
PRIMARY | |||
|
100000085210
Created by
admin on Fri Dec 15 15:01:03 UTC 2023 , Edited by admin on Fri Dec 15 15:01:03 UTC 2023
|
PRIMARY | |||
|
CHEMBL444
Created by
admin on Fri Dec 15 15:01:03 UTC 2023 , Edited by admin on Fri Dec 15 15:01:03 UTC 2023
|
PRIMARY | |||
|
2294
Created by
admin on Fri Dec 15 15:01:03 UTC 2023 , Edited by admin on Fri Dec 15 15:01:03 UTC 2023
|
PRIMARY | |||
|
200-331-2
Created by
admin on Fri Dec 15 15:01:03 UTC 2023 , Edited by admin on Fri Dec 15 15:01:03 UTC 2023
|
PRIMARY | |||
|
DTXSID5022643
Created by
admin on Fri Dec 15 15:01:03 UTC 2023 , Edited by admin on Fri Dec 15 15:01:03 UTC 2023
|
PRIMARY | |||
|
31252
Created by
admin on Fri Dec 15 15:01:03 UTC 2023 , Edited by admin on Fri Dec 15 15:01:03 UTC 2023
|
PRIMARY | |||
|
289
Created by
admin on Fri Dec 15 15:01:03 UTC 2023 , Edited by admin on Fri Dec 15 15:01:03 UTC 2023
|
PRIMARY | |||
|
C76526
Created by
admin on Fri Dec 15 15:01:03 UTC 2023 , Edited by admin on Fri Dec 15 15:01:03 UTC 2023
|
PRIMARY | |||
|
BARBITAL
Created by
admin on Fri Dec 15 15:01:03 UTC 2023 , Edited by admin on Fri Dec 15 15:01:03 UTC 2023
|
PRIMARY | |||
|
SUB06102MIG
Created by
admin on Fri Dec 15 15:01:03 UTC 2023 , Edited by admin on Fri Dec 15 15:01:03 UTC 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)